Solid Biosciences (SLDB) Cash from Investing Activities (2017 - 2026)

Solid Biosciences has reported Cash from Investing Activities for 10 years, with the latest figure at $44.8 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 262.98% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.8 million (up 372.13% YoY) and the FY2025 annual result came in at -$58.5 million, down 263.38% from the prior year.
• Cash from Investing Activities eased to $44.8 million in Q1 2026 per SLDB's latest filing, from $47.0 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $66.1 million in Q4 2022 and troughed at -$59.6 million in Q2 2022.
• A 5-year average of $2.3 million and a median of -$5.2 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities surged 107937.14% in 2022, then plunged 532.38% in 2025.
• Over 5 years, Cash from Investing Activities stood at $66.1 million in 2022, then slumped by 31.47% to $45.3 million in 2023, then decreased by 14.86% to $38.6 million in 2024, then advanced by 21.9% to $47.0 million in 2025, then dropped by 4.8% to $44.8 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $44.8 million, $47.0 million, and -$45.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.